dc.contributor.author | Cutsem, E. van | en |
dc.contributor.author | Dicato, M. | en |
dc.contributor.author | Geva, R. | en |
dc.contributor.author | Arber, N. | en |
dc.contributor.author | Bang, Y. | en |
dc.contributor.author | Benson, A. | en |
dc.contributor.author | Cervantes, A. | en |
dc.contributor.author | Diaz-Rubio, E. | en |
dc.contributor.author | Ducreux, M. | en |
dc.contributor.author | Glynne-Jones, R. | en |
dc.contributor.author | Grothey, Axel | en |
dc.contributor.author | Haller, D. | en |
dc.contributor.author | Haustermans, K. | en |
dc.contributor.author | Kerr, D. | en |
dc.contributor.author | Nordlinger, B. | en |
dc.contributor.author | Marshall, J. | en |
dc.contributor.author | Minsky, B. D. | en |
dc.contributor.author | Kang, Y. K. | en |
dc.contributor.author | Labianca, R. | en |
dc.contributor.author | Lordick, F. | en |
dc.contributor.author | Ohtsu, A. | en |
dc.contributor.author | Pavlidis, Nicholas | en |
dc.contributor.author | Roth, A. | en |
dc.contributor.author | Rougier, P. | en |
dc.contributor.author | Schmoll, H. J. | en |
dc.contributor.author | Sobrero, A. | en |
dc.contributor.author | Tabernero, Josep | en |
dc.contributor.author | Velde, C. van de | en |
dc.contributor.author | Zalcberg, J. | en |
dc.creator | Cutsem, E. van | en |
dc.creator | Dicato, M. | en |
dc.creator | Geva, R. | en |
dc.creator | Arber, N. | en |
dc.creator | Bang, Y. | en |
dc.creator | Benson, A. | en |
dc.creator | Cervantes, A. | en |
dc.creator | Diaz-Rubio, E. | en |
dc.creator | Ducreux, M. | en |
dc.creator | Glynne-Jones, R. | en |
dc.creator | Grothey, Axel | en |
dc.creator | Haller, D. | en |
dc.creator | Haustermans, K. | en |
dc.creator | Kerr, D. | en |
dc.creator | Nordlinger, B. | en |
dc.creator | Marshall, J. | en |
dc.creator | Minsky, B. D. | en |
dc.creator | Kang, Y. K. | en |
dc.creator | Labianca, R. | en |
dc.creator | Lordick, F. | en |
dc.creator | Ohtsu, A. | en |
dc.creator | Pavlidis, Nicholas | en |
dc.creator | Roth, A. | en |
dc.creator | Rougier, P. | en |
dc.creator | Schmoll, H. J. | en |
dc.creator | Sobrero, A. | en |
dc.creator | Tabernero, Josep | en |
dc.creator | Velde, C. van de | en |
dc.creator | Zalcberg, J. | en |
dc.date.accessioned | 2018-06-22T09:53:25Z | |
dc.date.available | 2018-06-22T09:53:25Z | |
dc.date.issued | 2011 | |
dc.identifier.uri | https://gnosis.library.ucy.ac.cy/handle/7/41830 | |
dc.description.abstract | Well-recognized experts in the field of gastric cancer discussed during the 12th European Society Medical Oncology (ESMO)/World Congress Gastrointestinal Cancer (WCGIC) in Barcelona many important and controversial topics on the diagnosis and management of patients with gastric cancer. This article summarizes the recommendations and expert opinion on gastric cancer. It discusses and reflects on the regional differences in the incidence and care of gastric cancer, the definition of gastro-esophageal junction and its implication for treatment strategies and presents the latest recommendations in the staging and treatment of primary and metastatic gastric cancer. Recognition is given to the need for larger and well-designed clinical trials to answer many open questions. © The Author 2011. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. | en |
dc.language.iso | eng | en |
dc.source | Annals of Oncology | en |
dc.subject | Cisplatin | en |
dc.subject | Fluorouracil | en |
dc.subject | Human | en |
dc.subject | Patient care | en |
dc.subject | Humans | en |
dc.subject | Advanced cancer | en |
dc.subject | Computer assisted tomography | en |
dc.subject | Priority journal | en |
dc.subject | Prognosis | en |
dc.subject | Neutropenia | en |
dc.subject | Oxaliplatin | en |
dc.subject | Cancer staging | en |
dc.subject | Drug fatality | en |
dc.subject | Docetaxel | en |
dc.subject | Neoplasm metastasis | en |
dc.subject | Overall survival | en |
dc.subject | Survival rate | en |
dc.subject | Epirubicin | en |
dc.subject | Folinic acid | en |
dc.subject | Irinotecan | en |
dc.subject | Trastuzumab | en |
dc.subject | Meta analysis (topic) | en |
dc.subject | Genetic predisposition to disease | en |
dc.subject | Risk factors | en |
dc.subject | Conference paper | en |
dc.subject | Side effect | en |
dc.subject | Stomach neoplasms | en |
dc.subject | Cancer adjuvant therapy | en |
dc.subject | Stomach cancer | en |
dc.subject | Continuous infusion | en |
dc.subject | Placebo | en |
dc.subject | Cancer incidence | en |
dc.subject | Cardiovascular risk | en |
dc.subject | Prevalence | en |
dc.subject | Nuclear magnetic resonance imaging | en |
dc.subject | Drug dose reduction | en |
dc.subject | Bevacizumab | en |
dc.subject | Gimeracil plus oteracil potassium plus tegafur | en |
dc.subject | Fluorodeoxyglucose f 18 | en |
dc.subject | Positron emission tomography | en |
dc.subject | Carcinoembryonic antigen | en |
dc.subject | Infection control | en |
dc.subject | Caloric intake | en |
dc.subject | Capecitabine | en |
dc.subject | Phase 3 clinical trial (topic) | en |
dc.subject | Primary tumor | en |
dc.subject | Metastasis potential | en |
dc.subject | Practice guidelines as topic | en |
dc.subject | Ca 19-9 antigen | en |
dc.subject | Computer assisted radiotherapy | en |
dc.subject | Cyanocobalamin | en |
dc.subject | Folic acid | en |
dc.subject | Cancer susceptibility | en |
dc.subject | Endoscopic echography | en |
dc.subject | Endoscopic mucosal resection | en |
dc.subject | Esophageal adenocarcinoma | en |
dc.subject | Helicobacter infection | en |
dc.subject | Helicobacter pylori | en |
dc.subject | Intensity modulated radiation therapy | en |
dc.subject | Lower esophagus sphincter | en |
dc.subject | Stomach adenocarcinoma | en |
dc.title | The diagnosis and management of gastric cancer: Expert discussion and recommendations from the 12th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2010 | en |
dc.type | info:eu-repo/semantics/article | |
dc.identifier.doi | 10.1093/annonc/mdr284 | |
dc.description.volume | 22 | |
dc.description.issue | SUPPL. 5 | en |
dc.description.startingpage | v1 | |
dc.description.endingpage | v9 | |
dc.author.faculty | Ιατρική Σχολή / Medical School | |
dc.author.department | Ιατρική Σχολή / Medical School | |
dc.type.uhtype | Article | en |
dc.contributor.orcid | Pavlidis, Nicholas [0000-0002-2195-9961] | |
dc.gnosis.orcid | 0000-0002-2195-9961 | |